옵션 체인은 다양한 행사가격과 만기일에 대한 Outset Medical의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Outset Medical에 대한 시장 심리를 평가합니다..

Outset Medical (NASDAQ:OM) 주식, 옵션 체인

Outset Medical

Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.

Cryptocurrency Photo by CMP_NZ on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

Movers

Trading Ideas

$ADA

$BTC

$DOGE

$ETH

$SOL

암호화폐 섹터는 일부 시가총액 상위 코인이 두 자릿수 손실을 기록하면서 1분기를 하락세로 마감했다.
무슨 일 있었나: 전체 암호화폐 시가총액은 1월 1일 3조 2,600억 달러에서 분기 말 2조 6,800억 달러로 줄어 17% 감소했다.

트럼프 관세 우려로 비트코인·도지코인 흔들리는 가운데 490% 급등한 암호화폐는?

Cryptocurrency Photo by Avi Rozen on Shutterstock

$LTC

$SHIB

$TAO

$XRP

TSX:TAO

암호화폐 시장은 지난주에 많은 상위 코인들이 두 자릿수 퍼센트 상승을 기록하면서, 평가액의 상당 부분을 회복했다.
무슨 일 있었니: 탈중앙화 인공지능 플랫폼 비트텐서(Bittensor)의 네이티브 토큰인 TAO가 지난주 30% 상승하면서 시장을 주도했다.
암호화폐 대기업 디지털 커런시 그룹(Digital Currency Group)의 대표인 바리 실버트(Barry Silbert)가 주주들에게 보내는 서한에서 탈중앙화 AI에 대한 낙관적인 전망을 표명하면서 모멘텀을 얻었다.

지난주 비트코인·이더리움·도지코인 상승세 속 라이트코인 25% 급등, 무슨 일일까?

$DEXE

지난주 암호화폐 시장은 여러 가지 악재가 겹치며 시장 가치가 큰 폭으로 하락했다. 그러나 일부 코인은 전반적인 하락세를 극복하고 상당한 상승세를 기록했다.
무슨 일 있었나: 탈중앙화 거래소 하이퍼리퀴드(Hyperliquid)의 네이티브 토큰인 HYPE가 한 주 동안 7.5% 상승하며 상승률 1위를 차지했다. 이 코인은 작년 한 해 동안 586%의 엄청난 상승률을 기록했다. 하이퍼리퀴드는 자체 레이어-1 블록체인을 활용하는 탈중앙화 거래 플랫폼이다.

지난주 비트코인·도지코인 하락에도 상승한 암호화폐는?

Outset Medical Inc

MANTRA DAO

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. - American Depositary Shares each representing 8 Series B shares

Grupo Aeroportuario del Centro Norte SAB de CV

Omagine Inc

Tidal Trust III VistaShares Target 15 Berkshire Select Income ETF

Origin Protocol - United States Dollar

Omnicom Group Inc

Old Market Capital Corporation - Common Stock

Old Market Capital Corp

Omnicell Inc

ORMAND INDUSTRIES INC by Ormand Industries, Inc.

Ormand Inds Inc

Omeros Corp

Odyssey Marine Exploration, Inc. - Common Stock

Odyssey Marine Exploration Inc

OneMain Holdings Inc

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 1000 Dynamic Multifactor ETF

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 2000 Dynamic Multifactor ETF

OmiseGO - United States Dollar

OMEGA THERAPEUTICS INC by Omega Therapeutics, Inc.

Omega Therapeutics Inc

OMAI GOLD MINES CORP by OMAI GOLD MINES CORP.

Omai Gold Mines Corp

OMEGA OIL NL by OMEGA OIL NL

OMEGA PAC RES INC by Omega Pacific Resources Inc.

Omega Pacific Resources Inc

Ohmyhome Ltd

Omni Health Inc

OM HOLDINGS INTL INC by OM Holdings International, Inc.

Om Holdings International Inc

OM Holdings Ltd

Owens & Minor Inc

Singular Genomic Systems Inc COM NEW

Omid Holdings Inc

oOh media Ltd

OMNIMMUNE HOLDINGS INC by Omnimmune Holdings, Inc.

Omnimmune Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OMN - United States Dollar

Omni Network - United States Dollar

Omphalos Corp

OMNIQ Corp

OMRON Corp

Orthometrix Inc

OMS Energy Technologies Inc

OMNITEK ENGINEERING CORP by Omnitek Engineering Corp.

OmniTek Engineering Corp

Omni Ventures Inc

OMV AG

Omnia Wellness Inc

Osisko Metals Inc

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the <a href="https://pr.report/ab65">2025 Genetic Toxicology Association Annual Meeting</a>, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.

Biotech

General

IGC Pharma Presents Its Latest Scientific Poster, Titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," At The 2025 Genetic Toxicology Association Annual Meeting

Shares of Chinese electric vehicle (EV) maker XPeng Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged 7.7% to $21.15 Monday morning following news that the U.S. and China reached a temporary truce in their ongoing trade dispute, agreeing to significantly roll back tariffs on <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">most goods for 90 days</a>.
What To Know: XPeng, an EV manufacturer based in Guangzhou, stands to benefit directly from the <a href="https://www.benzinga.com/topic/tariffs">tariff</a> reduction. The company has been aggressively expanding its footprint in Europe and exploring entry into the North American market.
With tariffs now lowered from 125% to just 10% on most categories, XPeng's cost structure for potential U.S. exports and imported U.S. components likely improves considerably.
Moreover, China's suspension of non-tariff countermeasures, including sanctions and export restrictions on high-tech materials, could ease XPeng's access to advanced semiconductors and batteries, critical to its XNGP autonomous driving platform and upcoming G6 and X9 models.
The easing of geopolitical tensions could also boost investor confidence in XPeng's international strategy and alleviates risks tied to supply chain disruptions and trade barriers.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45327340/3-best-energy-stocks-to-buy-right-now">3 Best Energy Stocks To Buy Right Now</a>
<h2 class="wp-block-heading">How To Buy XPEV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in XPeng&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XPEV has a 52-week high of $27.16 and a 52-week low of $6.60.

XPEV

XPeng (XPEV) Stock Surges On US–China Tariff Easing: What's Going On?

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from the same period last year.

Earnings

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Jianzhi Education Technology Group Company Limited ("Jianzhi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>), a leading provider of digital educational content in China, today announced it had partnered with China Telecom, one of the world's largest and most influential integrated communications and technology providers. This major collaboration represents a critical step forward in integrating Jianzhi's robust education platforms into China Telecom's expansive cloud center infrastructure.
Following extensive negotiations between the two organizations, this landmark collaboration aims to reshape the future of education by embedding cutting-edge AI-generated content (AIGC) and digital human technologies into every facet of the learning experience.
China Telecom, a Fortune Global 500 company with over 425 million mobile subscribers and operating revenues amounting to US$72.5 billion in 2024, brings immense infrastructure strength, technical support, and national reach to the project. By aligning with&nbsp;Jianzhi, China Telecom will further extend its strategic presence in the digital education space through seamless cloud-based delivery. Jianzhi's cloud-ready educational content and platforms will support the joint development of new cloud-native applications and services tailored to the needs of learners and institutions nationwide.

Jianzhi Education Technology Announces It Had Partnered With China Telecom, Collaboration Aims To Reshape The Future Of Education By Embedding Cutting-Edge AI-Generated Content And Digital Human Technologies Into The Learning Experience

Earnings Beats

CORRECTION: NRG Energy Q1 Adj. EPS $2.62 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

WIIM

RMTI

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

MEGL

Magic Empire Global shares are trading lower after the company announced it filed a prospectus for the offer and sale of up to 15 million shares.

Guggenheim analyst Curry Baker maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $61 to $60.

Price Target

Analyst Ratings

DKNG

Guggenheim Maintains Buy on DraftKings, Lowers Price Target to $60

Management

NWBI

Northwest Bancshares Announces Timothy B. Fannin Has Stepped Down As Board Chair, And Has Been Succeeded By Vice Chair Timothy M. Hunter

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Richard Close downgraded DocGo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) from Buy to Hold and lowered the price target from $5 to $1.45. DocGo shares closed at $1.40 on Friday. <a href="https://www.benzinga.com/quote/dcgo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst Michael Petusky downgraded the rating for ModivCare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) from Outperform to Market Perform. ModivCare shares closed at $1.17 on Friday. <a href="https://www.benzinga.com/quote/modv/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and cut the price target from $45 to $30. Amphastar Pharma shares closed at $24.11 on Friday. <a href="https://www.benzinga.com/quote/amph/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Zhihan Ma downgraded the rating for Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Market Perform to Underperform and lowered the price target from $97 to $82. Target shares closed at $96.40 on Friday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Stephen Laszczyk downgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Buy to Neutral and slashed the price target from $35 to $28. Warner Music shares closed at $27.36 on Friday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png" alt="" class="wp-image-911928" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

AMPH

DCGO

MODV

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Superior Industries International shares are trading lower after the company reported worse-than-expected Q1 EPS results and announced it is withdrawing its FY25 guidance.

Inter &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.12 by 8.33 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $313.81 million which missed the analyst consensus estimate of $327.02 million by 4.04 percent. This is a 10.88 percent increase over sales of $283.02 million the same period last year.

Earnings Misses

INTR

Inter & Co Q1 GAAP EPS $0.11 Misses $0.12 Estimate, Sales $313.81M Miss $327.02M Estimate

In the face of ongoing trade tensions,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly contemplating raising the prices for its forthcoming fall iPhone models, while also planning to introduce new features and design changes.
What Happened: The iPhone maker is planning a price hike but is keen to dispel any notion that a possible price increase is tied to U.S. tariffs on Chinese goods, where most of its devices are assembled, according to a <a href="https://www.wsj.com/tech/apple-iphone-price-increase-2eaebb14">report</a> by The Wall Street Journal on Monday.
Facing supply chain pressures, Apple is considering raising iPhone prices to protect profits, while seeking non-tariff reasons to justify the hike, though new feature details remain unclear. Notably, the company is preparing to launch new iPhones this fall, which will include design updates such as an ultrathin profile.
CEO Tim Cook has been navigating the U.S.-China trade tensions, which threaten Apple's supply chain. In response, he has increased inventory levels and moved some U.S.-bound manufacturing to India. However, production of Apple's high-end models like the Pro and Pro Max will largely remain in Chinese factories, as India's infrastructure and technical capacity are not yet advanced enough to support large-scale production on par with China's current capabilities, sources told the publication.
Apple is also exploring the possibility of shifting some iPhone production to the U.S., a move that could take several years. In the meantime, its shift toward manufacturing smartphones in India for export to the U.S. is expected to gain momentum.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a>
Why It Matters: Apple&#8217;s potential price hike comes amid a series of strategic moves and product innovations. Earlier in May, Apple&#8217;s CEO, Tim Cook, discussed the possibility of <a href="https://www.benzinga.com/markets/25/05/45162929/tim-cook-tells-commerce-secretary-lutnick-how-apple-could-bring-iphone-manufacturing-to-us">relocating iPhone</a> production to the U.S. with U.S. Commerce Secretary Howard Lutnick. This was followed by the news of Apple bracing for a $900 million <a href="https://www.benzinga.com/markets/25/05/45185355/apple-braces-for-900-million-tariff-impact-tim-cook-discusses-potential-iphone-manufacturing-shift-to-us-with-lutnick-and-more-this-week-in-appleverse">tariff impact</a>, as revealed by Cook during the company&#8217;s fiscal second-quarter earnings call.
Notably, Apple is reportedly planning a <a href="https://www.benzinga.com/tech/25/05/45338324/apples-2027-vision-foldable-iphones-smart-glasses-and-ai-innovations">significant year </a>in 2027, with plans to introduce a range of innovative devices and features, including a foldable iPhone and smart glasses. These developments highlight Apple&#8217;s ongoing efforts to navigate trade tensions while maintaining its commitment to innovation and customer satisfaction.
Despite these strategies, Apple may still find it challenging to counterbalance China tariff costs solely through supplier savings, potentially affecting its profit margin unless it can increase prices. However, executives are wary about attributing price increases to tariffs, after the White House slammed Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), displaying tariffs beside its product prices and calling it a &#8216;hostile act&#8217;.
Apple holds a momentum rating of 49.76% and a quality rating of 82.46%, according to&nbsp;<a href="https://www.benzinga.com/quote/AAPL" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Apple stock has declined 18.59% during the year-to-date period.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45338404/charlie-mungers-financial-success-advice-i-avoided-standard-ways-of-failing-because-my-game-in-life-was-always-to-avoid-all-standard-ways-of-failing" target="_blank" rel="noreferrer noopener">Charlie Munger&#8217;s Financial Success Advice: &#8216;I Avoided Standard Ways Of Failing, Because My Game in Life Was Always To Avoid All Standard Ways of Failing&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

AMZN

Apple May Hike iPhone Prices This Fall, Steering Clear Of Tariff Blame: Report

CTMX

CytomX Therapeutics shares are trading higher. The company announced a $100 million offering of 76.9 million shares at $1.30 per share.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $55 to $45.

NTLA

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) (the "Company") is rescheduling the announcement of its financial results for the first quarter of 2025 to Wednesday, May 14th, 2025 at 4:00 P.M. Eastern Time to announce the closing of the Jamaica transaction, and announce an update to the use of proceeds. A copy of the press release and an earnings supplement will be posted to the Investors section of the Company's website, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.newfortressenergy.com&amp;esheet=54253060&amp;newsitemid=20250512039219&amp;lan=en-US&amp;anchor=www.newfortressenergy.com&amp;index=1&amp;md5=e3938874f7198884392d06c505510a99">www.newfortressenergy.com</a>.
The Company will hold a conference call on Wednesday, May 14th, 2025 at 4:30 P.M. Eastern Time. The conference call may be accessed by dialing (888) 256-1007 (toll-free from within the U.S.) or +1 (323) 701-0225 (from outside of the U.S.) fifteen minutes prior to the scheduled start of the call; please reference "NFE First-Quarter 2025 Earnings Call" or conference code 8378656.

New Fortress Energy Reschedules Q1 2025 Earnings Release And Conference Call To May 14, 2025

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) with a Buy and maintains $10 price target.

TVGN

D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

GD Culture Group shares are trading higher after the company announced a $300 million stock purchase agreement to support its crypto treasury expansion.

Mitsubishi Estate Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MITEY#OTC">MITEY</a>) reported quarterly earnings of $0.44 per share. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $3.49 billion in sales this quarter. This is a 10.47 percent decrease over sales of $3.90 billion the same period last year.

MITEY

Mitsubishi Estate Co Q4 EPS $0.44 Down From $0.48 YoY, Sales $3.49B Down From $3.90B YoY

Legal

Press Releases

Kuehn Law Encourages Investors of Outset Medical, Inc. to Contact Law Firm

Outset Medical Announces Resolution of Warning Letter

Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference

Outset Medical Announces One-for-Fifteen Reverse Stock Split

Alert to Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra LifeSciences Holdings Corporation (NASDAQ: IART); Outset Medical, Inc. (NASDAQ: OM); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Is Investigating Claims on Your Behalf

Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

OUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Outset Medical

Outset Medical (OM) 옵션

Outset Medical (NASDAQ:OM) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌